Neurocrine Biosciences
NBIX
NBIX
174 hedge funds and large institutions have $3.38B invested in Neurocrine Biosciences in 2015 Q1 according to their latest regulatory filings, with 56 funds opening new positions, 56 increasing their positions, 55 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more call options, than puts
Call options by funds: $ | Put options by funds: $
31% more funds holding
Funds holding: 133 → 174 (+41)
2% more repeat investments, than reductions
Existing positions increased: 56 | Existing positions reduced: 55
Holders
174
Holding in Top 10
4
Calls
$32.5M
Puts
$22.3M
Top Buyers
| 1 | +$90.9M | |
| 2 | +$74.8M | |
| 3 | +$67M | |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$62.8M |
| 5 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$51.6M |
Top Sellers
| 1 | -$28.8M | |
| 2 | -$28.3M | |
| 3 | -$22.7M | |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$19.8M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
-$16.7M |